Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone.
OBJECTIVE
The purpose of this comparative outcome study was to investigate whether the effects of exposure in vivo treatment for panic disorder with agoraphobia could be enhanced by adding interventions specifically for panic attacks before the start of exposure treatment. The additional effect of two types of treatment for panic attacks--pharmacological (fluvoxamine) and psychological (repeated hyperventilation provocations and respiratory training)--was examined. Thus, the combined treatment of panic interventions with exposure in vivo could be compared to exposure in vivo alone.


METHODS
Ninety-six patients were randomly assigned to four treatment conditions: double-blind, placebo-controlled fluvoxamine followed by exposure in vivo, psychological panic management followed by exposure, and exposure in vivo alone. Outcome was assessed by self-report measures, a standardized multitask behavioral avoidance test, and continuous monitoring of panic attacks. Seventy-six patients completed the study.


RESULTS
All four treatments were effective and resulted in a significant decrease of agoraphobic avoidance. Moreover, the combination of fluvoxamine and exposure in vivo demonstrated efficacy superior to that of the other treatments and had twice as large an effect size (difference between pre- and posttreatment scores) on self-reported agoraphobic avoidance. The other treatments did not differ among each other in effectiveness.


CONCLUSIONS
Results of the study indicate that the short-term outcome of exposure in vivo treatment can be enhanced by adding fluvoxamine treatment. Psychological panic management combined with exposure was not superior to exposure alone of equal duration.
de Beurs
E
E
Department of Clinical Psychology, University of Amsterdam, The Netherlands.
van Balkom
A J
AJ
Lange
A
A
Koele
P
P
van Dyck
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D000553:Ambulatory Care; D001521:Behavior Therapy; D001945:Breathing Exercises; D003131:Combined Modality Therapy; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D006985:Hyperventilation / Q000523:psychology; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D010352:Patient Dropouts; D010555:Personality Inventory; D010919:Placebos; D016896:Treatment Outcome
D010919:Placebos; D016666:Fluvoxamine